Michael Higgins


Michael has more than 25 years of experience in the biopharmaceutical industry working with large multi-national organizations and small entrepreneurial firms.

Michael has held leadership roles in Finance, Operations, and Business Development, and is currently a Polaris advisor.

He is a Board member for three public companies: Genocea Biosciences, Pulmatrix, Inc. and Voyager Therapeutics. In addition, he is the executive chairman of Kindex Pharmaceuticals and serves on the Board of Marauder Therapeutics, Sea Pharmaceuticals, and Private Equity Access Fund, II.

Michael served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals from 2003 through 2014. He played a key role in all aspects of Ironwood’s evolution from a privately funded discovery organization through its initial public offering and the launch of its’ first commercial product. Under his leadership, the company was able to raise more than a billion dollars to help support the development of the business during that period.

In 2014, Michael was named Boston Business Journal’s CFO of the Year. Prior to his work at Ironwood, he spent seven years at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development.

While at Genzyme, he was involved with multiple businesses including the cell therapy, gene therapy, and orphan disease business units. He served as Chief Financial Officer of Procept, Inc. prior to his time at Genzyme – leading the company from founding through its’ initial public offering.

Michael began his pharmaceutical career as a sales representative for Schering-Plough Corporation. He earned his Bachelor of Science degree from Cornell University and holds an M.A. in Business Administration from the Amos Tuck School of Business at Dartmouth College.